Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-100 + Carboplatin/Etoposide/Atezolizumab in Untreated Extensive-Stage SCLC
NCT04560972Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- May 2021
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LB-100 in small cell lung cancer (SCLC), sponsored by City of Hope. Primary endpoint: Recommended Phase II Dose at 21 days. Started May 2021; status: active, not recruiting.
02
Drugs
LB-100
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04560972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560972.